Sunshine Biopharma (SBFM) Long-Term Deferred Tax (2016 - 2025)

Sunshine Biopharma's Long-Term Deferred Tax history runs 9 years deep, the most recent figure standing at $7.8 million for Q4 2025.

• Quarterly Long-Term Deferred Tax rose 8341.22% year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (up 8341.22% YoY) and the FY2025 annual result came in at $7.8 million, up 8341.22% from the prior year.
• Long-Term Deferred Tax was $7.8 million for Q4 2025 at Sunshine Biopharma, up from $92234.0 in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $28.0 million in Q4 2021 and bottomed at $43032.0 in Q4 2022.
• A 4-year average of $5.2 million and a median of $92234.0 in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax sank 99.85% — and 2025, when it surged 8341.22%.
• Sunshine Biopharma's Long-Term Deferred Tax stood at $28.0 million in 2021, then sank by 99.85% to $43032.0 in 2022, then soared by 114.34% to $92234.0 in 2024, then jumped by 8341.22% to $7.8 million in 2025.
• Business Quant data shows SBFM's Long-Term Deferred Tax at $7.8 million in Q4 2025, $92234.0 in Q3 2025, and $92234.0 in Q2 2025.